Area of expertise: Infectious diseases, anti-infectives (antibacterials, antifungals, antivirals, vaccines, immunoglobulins).I am working mainly with clinical evaluations (efficacy, safety, benefit/risk) of marketing authorisation applications (new chemical entities, generics), variations, safety follow-up assessments (periodic safety update reports, risk management plans), scientific advice to industry (national and centralised advice).Member (former Chair) of the Infectious Diseases Working Party (IDWP; a CHMP working party).Alternate member of the Scientific Advice Working Party (SAWP; a CHMP working party).Co-opted member of the Swedish Reference Group for Antibiotics (SRGA/RAF).Former Co-opted member of the Swedish Reference Group for Antifungal Agents (RAM).

Resident physician 2001-2006Specialist in Infectious Diseases 2006PhD in Infectious Diseases 2011Director of studies 2011-2013 (for resident physicians in Infectious Diseases)Publications:Lignell A, Siegbahn A, Stridsberg M, Pauksen K, Gedeborg R, Sjolin J. Low utilisation of unactivated protein C in a patient with meningococcal septic shock and disseminated intravascular coagulation. Acta Anaesthesiol Scand 2003; 47(7): 897-900.Lignell A, Johansson A, Lowdin E, Cars O, Sjolin J. A new in-vitro kinetic model to study thepharmacodynamics of antifungal agents: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole. Clin Microbiol Infect 2007; 13(6): 613-9.Lignell A, Lowdin E, Cars O, Sjolin J. Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model. J Antimicrob Chemother 2008; 62(1): 142-8.Bergman A, Lignell A, Melhus A. The first documented case of Aspergillus cardiac surgical site infection in Sweden: an epidemiology study using arbitrarily primed PCR. APMIS 2009; 117(8): 568-74.Lignell A, Lowdin E, Cars O, Sanglard D, Sjolin J. Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone. Antimicrob Agents Chemother 2011; 55(4): 1629-37.Lignell A, Lowdin E, Cars O, Chryssanthou E, Sjolin J. Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration. AntimicrobAgents Chemother 2011; 55(7): 3099-104.Lignell A. In vitro pharmacodynamics of antifungal agents in the treatment of Candida infections. (Doctoral thesis 2011); URL: http://uu.diva-portal.org/smash/record.jsfpid=diva2:374279